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1. Introduction 
Reduction of the stressful effects of extracorporeal circulation is a major target in 
hemodialysis (HD) therapy. These effects can be attributed to the HD-associated uremic 
comorbidity and the oxidative and non-oxidative events that occur because of the 
extracorporeal treatment. Anemia, cardiovascular disease, chronic inflammation, 
immunosuppression and intradialytic hypotension are among the most common 
complications in patients receiving HD, which show a causal relationship with oxidative 
stress (Galli, 2002 and Del Vecchio et al., 2011). During HD, the patient’s blood is repeatedly 
exposed to components of the extracorporeal circulation, a key component of which is the 
hollow-fiber dialyzer membrane. This phenomenon may lead to leukocyte and platelet 
activation, thereby causing oxidative stress. Moreover, bioactive contaminants, e.g., bacterial 
endotoxins in the dialysis fluids, to which the patient’s blood is eventually exposed through 
the dialyzer membrane, may further sustain leukocyte activation. These variables, which are 
usually included under the definition of “bio-incompatibility,” should be carefully 
monitored by dialysis centers because these variables are responsible for causing pro-
inflammatory events, oxidative stress, and pro-thrombotic effects. Leukocyte activation and 
oxidative stress are also reported to cause erythrocyte damage that is further aggravated by 
shear stress and other mechanical injuries. Plasma proteins and lipids show signs of 
oxidative damage (Piroddi et al., 2007 and Galli, 2007), and this may influence the burden of 
uremic toxicity by inducing cell and tissue reactions, abnormal metabolism of these 
oxidation products, vascular and immune reactions, etc. To reduce the risk of oxidative 
stress and other adverse reactions that can be caused by poor biocompatibility of HD 
treatment, highly purified dialysis fluids and dialyzer membranes with greater 
biocompatibility have been developed, and are currently under investigation for further 
improvement. 
The bio-incompatibility of prototypical dialyzer membranes made of regenerated 
cellulose has been associated with the contact of blood components with the hydroxyl 
groups of beta-D-glucose. These groups trigger intradialytic activation of the complement 
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system and cause leucopenia (Rousseau et al., 1999). Biocompatibility of regenerated 
cellulose dialyzer membranes was tentatively improved by the chemical modification of 
the hydroxyl groups, e.g., by acetylation to obtain tri-acetate cellulose, or by adding 
polyethylene glycol (PEG) chains to obtain PEG-grafted cellulose. Another and more 
successful approach was the de novo development of synthetic polymer membranes such 
as polysulfone or polyether sulfone membranes with no bio-incompatible groups in their 
chemical structures (Bowry, 2002). At present, high-flux synthetic membranes are more 
frequently used, and represent a cost-effective solution with proven clinical superiority 
over cellulosic membranes (Krane et al., 2007). 
Antioxidants such as vitamin C, vitamin E, and glutathione have been used as oral 
supplements to alleviate HD-induced oxidative stress (Galli and Azzi, 2010). The clinical 
course of chronic kidney disease (CKD) includes a progressive decrease in the levels of blood 
antioxidants such as vitamins C, vitamin E, and glutathione. As a result, CKD patients who 
undergo regular HD treatment show severe deficiencies, particularly of water-soluble 
antioxidants (such as vitamin C). Few studies, however, provided clear evidence of the clinical 
advantage of oral antioxidants. The most convincing evidence was obtained from the 
randomized clinical trial on vitamin E supplementation in HD patients. This trial, known as 
SPACE study (Boaz et al., 2000), showed a significant reduction (54%) of the primary endpoint 
variable (a composite variable including myocardial infarction, ischemic stroke, peripheral 
vascular disease,  and unstable angina) and 70% reduction in myocardial infarction. 
One of the most original approaches for antioxidant therapy in HD involved the use of 
vitamin E as a lipophilic modifier of the surface of the dialysis membrane. The bonded 
vitamin E on the surface of the dialyzer membrane is expected to reduce the production of 
reactive oxygen species (ROS) at the site where blood cells are exposed to the dialyzer 
membrane, thereby providing the blood cells with antioxidant protection in a timely and 
targeted manner. Two generations of vitamin E-bonded dialyzers based on this concept, 
namely, cellulosic- and polysulfone-based membrane dialyzers, have been successfully 
developed and launched in the market over the last 2 decades. This chapter provides a 
review of the literature and a critical examination of the available clinical data on vitamin E-
bonded dialyzer membranes. 
2. Cellulose-based vitamin E-bonded dialyzer membranes  
2.1 Development 
In 1990, cellulose-based vitamin E-bonded dialyzer membranes (Excebrane) were developed 
and introduced into the market by Terumo Corporation. The base membrane was made of 
regenerated cellulose hollow fiber, and the surface of the hollow fiber was covalently modified 
by hydrophilic polymers as well as by oleic alcohol. Vitamin E (-tocopherol) was then 
bonded to oleic alcohol via hydrophobic interaction. Sasaki et al., 2000, reported the outline of 
the production process as well as the results of in vitro and in vivo studies on Excebrane, which 
showed much better biocompatibility than the original regenerated cellulose membrane. 
2.2 Clinical outcomes 
Early trials using Excebrane indicated that its use would have positive clinical effects (Galli, 
2002). The potential therapeutic effects of using this membrane in HD were reduction of 
oxidative stress and inflammation. Cardiovascular endpoints were investigated in several 
small clinical trials and in a meta-analysis of 14 peer-reviewed articles by Sosa et al., 2006; 
these studies concluded that Excebrane treatment was associated with a significant decrease in 
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the plasma levels of lipid-peroxidation biomarkers, thereby suggesting the potential benefit of 
these membranes in clinical usage. Actually, these biomarkers have a cause-effect relationship 
with low density lipoprotein (LDL) damage and endothelial dysfunction in CKD. Preliminary 
evidence of better management of uremic anemia by these dialyzer membranes was obtained 
in the pioneering studies by Usberti et al., 2002; Nakatani et al., 2003; and Kobayashi et al., 
2003. These authors found improved erythrocyte life span and rheology in patients receiving 
HD with Excebrane. A larger multicenter study (172 patients) reported by Cruz et al., 2008, 
confirmed that the impact of Excebrane dialyzers on anemia parameters was better than that of 
other high-flux biocompatible dialyzer membranes, including cellulose acetate, polysulfone, 
and polymethylmethacrylate. 
Other reports demonstrated positive effects such as (1) decreased oxidative stress (Tarng et al., 
2000; Miyazaki et al., 2000; Clermont et al., 2001; Westhuyzen et al., 2003; Bufano et al., 2004; 
Mydlik et al., 2004; Calò et al., 2004; Yang et al., 2006; and Odetti et al., 2006), (2) suppression of 
leukocyte activation (Omata et al., 2000; Zaluska et al., 2001;Pertosa et al., 2002; Tsuruoka et al., 
2002; Libetta et al., 2004; and Kojima et al., 2005), (3) dosage reduction of anticoagulants 
(Huraib et al., 2000), (4) improved biocompatibility (Yoshida et al., 2002), and (5) decreased 
levels of advanced glycation end products (AGEs) (Baragetti et al., 2006). Moreover, a recent 
study reported by Kirmizis D et al., 2010, showed that the levels of inflammatory markers such 
as C-reactive protein (CRP), interleukin (IL)-6, and soluble intercellular adhesion molecule 
(sICAM)-1 in 35 patients treated with Excebrane were lower than those in the baseline 
evaluation carried out with conventional low- or middle-flux dialyzers. Whereas, no change 
was observed throughout the experimental period in a matched control group of 25 patients 
who underwent treatment with the unmodified dialyzers. 
3. Polysulfone-based vitamin E-bonded dialyzer membranes 
3.1 Development 
Synthetic membrane dialyzers have been developed by many manufacturers in the past 
decades to achieve higher depurative and biocompatibility standards. Polysulfone has 
shown better performance among these synthetic biomaterials; as a result, it has become 
popular in clinical practice (Bowry, 2002). In order to achieve the synergistic effect of the 
biocompatibility of synthetic membranes and the antioxidant activity of vitamin E, 
polysulfone-based vitamin E-coated membranes were developed and introduced in the 
market in 1998. These dialyzers were initially developed by Terumo Corporation; 
subsequently, they were produced using a new technique and are now manufactured by 
Asahi Kasei Kuraray Medical Co. Ltd., with the membrane name of VitabranE. Preliminary 
in vitro analyses on these membranes were reported by Sasaki, 2006; the antioxidant capacity 
of VitabranE was recently confirmed and quantified by Floridi A, et al., 2009, by means of in 
vitro re-circulation tests carried out on mini-module dialyzers. These tests, which used an 
unbiased procedure, showed that at least one-third of the vitamin E present on the 
membrane participates in the one-electron transfer reaction with transition metals. This 
reaction, together with scavenging of peroxyl radicals, characterizes the antioxidant 
mechanism of vitamin E and is of putative relevance in its biological function. 
3.2 Improvement of anemia 
On the basis of the early evidence obtained in the Excebrane studies described in section 2.2, 
VitabranE was proposed as a more biocompatible dialyzer membrane to achieve a better 
control of anemia in HD patients. This aspect was investigated in clinical trials that 
www.intechopen.com
 
Technical Problems in Patients on Hemodialysis 
 
298 
compared VitabranE with polysulfone membranes. A pilot study by Andrulli et al., 2010, 
carried out with a 2-arm randomized controlled design showed that 8-month treatment with 
VitabranE decreased the erythropoiesis-stimulating agent (ESA)–resistance index (ERI); ERI 
is calculated as the ratio between ESA dosage (IU/kg/w) and hemoglobin levels (g/dL). In 
the primary analysis, ERI showed no significant deference between the groups treated with 
VitabranE and the control polysulfone membrane. However, in the secondary analysis 
where the baseline parathyroid hormone (PTH) and serum vitamin E levels were included 
as covariates, the ERI was significantly decreased in the group treated with VitabranE than 
in the group treated with the control polysulfone membrane. Therefore, the authors 
concluded that VitabranE membranes have potentially beneficial effects on ERI of HD 
patients. This conclusion was confirmed in another and more recent multicenter study by 
Panichi et al., 2011. In this report, a crossover design was employed and 62 HD patients 
from 13 dialysis units were randomized to receive treatments with VitabranE or polysulfone 
dialyzer controls. The patients were studied for 2 steps of 6 months in each treatment. In this 
study, hemoglobin levels significantly increased after 6 months of VitabranE treatment, 
whereas these remained unchanged in the control group. Moreover, at the same ESA dose, 
the ERI was significantly lower during the VitabranE treatment period. 
Further support for the findings of these randomized trials came from a pilot cross-over 
study by Mandolfo et al. (in press), which was conducted on patients using central venous 
catheters for blood access. Sixteen patients were enrolled and divided into 2 treatment 
groups (VitabranE dialyzer versus synthetic membrane dialyzers) and were followed for 2 
periods of 6 months each. The results showed that the ERI decreased significantly in the 
group that received treatment with VitabranE, whereas it did not change in the control 
group. Hemoglobin levels were not affected; thus, the authors concluded that VitabranE 
membranes might help reducing the ESA dose required in anti-anemic therapy. 
3.3 Improvement of inflammatory markers 
In the report by Panichi et al., 2011, the authors observed that beside of ERI reduction, CRP 
and IL-6 levels decreased during VitabranE treatment, whereas no significant changes were 
found during the control polysulfone treatment. The study by Mandolfo et al. (in press) on 
catheterized patients with a high inflammatory burden also reported a better control of CRP 
levels during the VitabranE treatment. In these studies, a lower inflammatory response was 
associated with improved ERI, which is consistent with the role of chronic inflammation and 
oxidative stress as pathogenic factors of uremic anemia (Del Vecchio et al., 2011). 
Calò et al., 2011, conducted a 1-year study on 25 HD patients to evaluate the effects of 
VitabranE on the biochemical markers of inflammation. The authors employed a molecular 
approach by using immunoblot (western blot) analysis to assess the expression of p22phox, 
plasminogen activator inhibitor (PAI)-1, phosphorylated extracellular signal-regulated 
kinase (pERK)1/2 and heme oxygenase (HO)-1 in circulating mononuclear leukocytes at the 
beginning of the study and after 6 and 12 months of treatment with VitabranE. The 
treatment with VitabranE significantly decreased the expression of inflammatory markers of 
p22phox, PAI-1, and pERK1/2, while the treatment increased the expression of anti-
inflammatory marker of HO-1. 
3.4 Reduction in the levels of oxidative stress makers 
Preliminary investigations of blood levels of advanced protein oxidation products (AOPP) 
and fluorescent AGEs were performed in the randomized controlled pilot trial reported by 
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Andrulli et al., 2010. In this study, these protein-damaged markers were investigated as 
oxidative and carbonyl stress indices associated with the correction of ERI. Although IL-6 
and CRP levels were not affected, the 2 indices showed better control in the patients 
receiving with VitabranE than in those receiving treatment with polysulfone dialyzer (Galli 
et al., manuscript in preparation). 
Vitamin E-bonded dialyzer membranes were originally developed with the aim of reducing 
oxidative stress. As shown in the section 2.2, lowered lipid peroxidation was observed in 
clinical trials with Excebrane, a cellulose-based vitamin E-bonded membrane. In the case of 
VitabranE, 2 studies were conducted, considering LDL oxidation as an end point. Morimoto 
et al., 2005, reported that the 15 patients who received 6 months of treatment with VitabranE 
showed significant reduction in the levels of asymmetric dimethylarginine (ADMA), 
malondialdehyde low density lipoprotein (MDA-LDL), and oxidized low density 
lipoprotein (Ox-LDL). The levels returned to baseline when the membrane was changed to a 
polysulfone dialyzer membrane. In a matched control group, patients treated with 
polysulfone dialyzers showed no change in ADMA, Ox-LDL, and MDA-LDL levels during 
the entire treatment period of 18 months. The other report from Calò et al., 2011, showed 
that VitabranE improved the levels of inflammation markers and also reduced plasma levels 
of Ox-LDL, which was evaluated by enzyme-linked immunosorbent assay. 
3.5 Improvement of intradialytic hypotension 
Intradialytic hypotension (IDH) is a common clinical trait in HD patients. Matsumura et al., 
2010, conducted a pilot study to assess the effectiveness of VitabranE in improving IDH. 
Eight IDH patients who had been receiving HD with conventional dialyzers were switched 
to VitabranE dialyzers, and intradialytic blood pressure (BP) was monitored regularly for 10 
months. The results showed that hypotension, monitored during the session by measuring 
systolic BP (SBP), diastolic BP (DBP), and pulse pressure (PP), improved after changing the 
dialyzer membrane. Moreover, after 8 to 10 months, SBP recorded before dialysis was 
significantly lower than that at baseline, which suggests a stable improvement in the 
vascular compliance to intra- and inter-dialysis control of BP.  
3.6 Anticoagulation management 
In a recent report, Aoun et al., 2010, described the potential clinical advantages of VitabranE in 
anticoagulant management. In an observational trial, these authors evaluated the minimum 
requirement of low molecular weight heparin (LMWH) in pediatric dialysis patients. Seven 
children and adolescent patients received HD with VitabranE dialyzer and their LMWH dose 
was decreased every week without any other change in the clinical management; the findings 
of this study consistently indicated a lower requirement of anticoagulants, which may help 
reducing bleeding problems and simplifying post-dialysis hemostasis. 
4. Conclusion 
The available literature suggests that vitamin E bonding on the cellulosic membrane 
Excebrane can reduce oxidative stress, as assessed by the levels of lipid peroxidation 
markers, and improve laboratory indices of inflammation and uremic anemia. The newly 
developed synthetic polysulfone-based dialysis membrane VitabranE appears to produce 
even more relevant clinical advantages as it is a homologue of most widely used synthetic 
membrane dialyzers. Randomized studies carried out in the past few years, which have 
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reported positive effects on ERI and anemia management, provide convincing and clinically 
relevant evidence. Early findings also suggest a better control of inflammatory and oxidative 
stress parameters. Anticoagulation and IDH are other potentially relevant aspects in the 
clinical application of VitabranE. These results suggest that VitabranE has superior 
performance than other synthetic membranes. Further and more comprehensive trials are 
needed for detailed verification of these clinical outcomes. 
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